title: Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA.
authors.forename: L M
authors.initials: LM
authors.lastname: Krug
authors.forename: V A
authors.initials: VA
authors.lastname: Miller
authors.forename: G P
authors.initials: GP
authors.lastname: Kalemkerian
authors.forename: M J
authors.initials: MJ
authors.lastname: Kraut
authors.forename: K K
authors.initials: KK
authors.lastname: Ng
authors.forename: R T
authors.initials: RT
authors.lastname: Heelan
authors.forename: B A
authors.initials: BA
authors.lastname: Pizzo
authors.forename: W
authors.initials: W
authors.lastname: Perez
authors.forename: N
authors.initials: N
authors.lastname: McClean
authors.forename: M G
authors.initials: MG
authors.lastname: Kris
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy*; D047630:Depsipeptides; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage* / Q000009:adverse effects; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047630:Depsipeptides; D009842:Oligopeptides; C064570:dolastatin 10